Susceptibility and resistance of Gram-negative bacteria to a novel antimicrobial agent TGV-49
Our findings suggest TGV-49 as a potential alternative for combating MDR infections in clinical and agricultural settings.
Authors
- Semen A. Leyn (ORCID: https://orcid.org/0000-0002-9886-9120)
- Andrei L. Osterman (ORCID: https://orcid.org/0000-0002-3810-9824)
- Maria Vecherkovskaya (ORCID: https://orcid.org/0000-0003-3543-9884)
- George Tetz (ORCID: https://orcid.org/0000-0003-3205-9018)
- Marinela L. Elane (ORCID: https://orcid.org/0000-0002-8116-6058)
- Kristina M. Kardava (ORCID: https://orcid.org/0000-0002-3325-9436)
- Victor Tetz (ORCID: https://orcid.org/0000-0001-9047-6763)
Institutions
- Discovery Institute (US)
- Tesla Laboratories (United States) (US)
- Westchester Institute for Human Development (US)
Publication Details
- Journal
- Frontiers in Antibiotics
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3389/frabi.2025.1615821
- Primary Topic
- Antimicrobial Peptides and Activities
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Allergy and Infectious Diseases